|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 10,927,129: Scope, Claims, and Landscape
United States Patent 10,927,129, granted on February 23, 2021, to Novartis AG, covers novel crystalline forms of imatinib mesylate. These forms, designated as Form I and Form II, address issues with existing crystalline forms, particularly regarding their thermodynamic stability and dissolution profiles. The patent asserts control over specific polymorphic forms of imatinib mesylate, their preparation methods, and pharmaceutical compositions containing them. This analysis details the patent's scope, key claims, and the competitive landscape it navigates.
What is the Core Innovation Claimed by Patent 10,927,129?
The patent's central innovation lies in the identification and characterization of specific crystalline forms of imatinib mesylate. These forms are distinguished by their unique physicochemical properties, which are critical for drug formulation and efficacy.
Defining the Novel Crystalline Forms
Patent 10,927,129 defines imatinib mesylate Form I and Form II through a combination of analytical data, primarily X-ray powder diffraction (XRPD) patterns and differential scanning calorimetry (DSC) data.
- Form I: Characterized by a specific XRPD pattern with defined peaks at particular 2-theta angles and a distinct melting point observed in DSC.
- Form II: Also defined by its unique XRPD pattern and DSC thermogram, differentiating it from Form I and other known polymorphs.
The patent emphasizes that these forms are thermodynamically more stable and exhibit improved dissolution rates compared to previously disclosed crystalline forms of imatinib mesylate, such as the alpha and beta forms. This enhanced stability and dissolution are attributed to specific molecular arrangements within the crystal lattice.
What are the Key Claims Covered by the Patent?
The claims of Patent 10,927,129 are structured to provide broad protection over the identified crystalline forms and their use.
Claim 1: Product-by-Process for Form I
Claim 1 is a product-by-process claim for imatinib mesylate in a crystalline form identified as Form I. This claim is significant as it defines the product by the method of its production, indicating that the specific manufacturing process leads to the desired crystalline structure. The process involves steps such as dissolving imatinib and methanesulfonic acid in a specific solvent mixture and inducing crystallization under controlled conditions.
- Key Process Parameters: The claim details specific solvent compositions (e.g., mixtures of alcohols and water), temperature ranges for dissolution and crystallization, and cooling rates. These parameters are crucial for achieving the desired crystalline morphology and purity.
- Distinguishing Features: The resulting Form I is characterized by its XRPD data, which is appended to the patent document. This data includes specific diffraction angles and relative intensities of the X-ray peaks, serving as a fingerprint for Form I.
Claim 2: Product-by-Process for Form II
Similar to Claim 1, Claim 2 is a product-by-process claim for imatinib mesylate in a crystalline form designated as Form II. The process described in this claim also involves specific solvent systems and crystallization conditions that differ from those for Form I.
- Process Differentiation: The solvent systems and crystallization temperatures may vary, leading to the formation of the distinct Form II polymorph.
- Analytical Characterization: Form II is also identified by its unique XRPD pattern, distinct from Form I and other known polymorphs.
Claims Relating to Pharmaceutical Compositions
The patent also extends protection to pharmaceutical compositions containing these novel crystalline forms.
- Composition Claims: These claims cover formulations that include imatinib mesylate in either Form I or Form II, along with pharmaceutically acceptable carriers, diluents, or excipients.
- Dosage Forms: The compositions are intended for various dosage forms, including tablets and capsules, designed for oral administration.
Claims Related to Methods of Treatment
The patent includes claims for the use of these novel crystalline forms in treating conditions for which imatinib is indicated.
- Therapeutic Indications: These claims cover the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
- Method of Administration: The claims specify administering a therapeutically effective amount of imatinib mesylate in Form I or Form II.
Infringement Considerations
The scope of these claims means that any party seeking to manufacture, use, sell, or import imatinib mesylate in either Form I or Form II, or pharmaceutical compositions containing them, would require a license from Novartis AG. This is particularly relevant for generic manufacturers seeking to enter the market with bioequivalent versions of imatinib mesylate. The specificity of the XRPD data as a defining characteristic is a critical point for infringement analysis.
What is the Patent Landscape for Imatinib Mesylate Polymorphs?
The patent landscape for imatinib mesylate is characterized by extensive patenting of its various crystalline forms, salt forms, and related pharmaceutical compositions. This is a common strategy for blockbuster drugs to extend market exclusivity beyond the primary compound patent.
Pre-existing Patents on Imatinib Mesylate Forms
Prior to Patent 10,927,129, several patents were filed and granted covering different polymorphs of imatinib mesylate, most notably the alpha and beta forms. These earlier patents established a precedent for protecting specific solid-state forms of the drug.
- Novartis's Core Patents: Novartis, the originator of imatinib (Gleevec/Glivec), secured initial patents covering the imatinib compound itself and its initial crystalline forms. These patents have largely expired or are nearing expiration in major markets.
- Alpha and Beta Forms: The alpha and beta crystalline forms of imatinib mesylate were widely studied and patented. These forms have different physical properties and were the subject of numerous patent disputes, particularly during the early generic entry phase.
Patent 10,927,129 in the Context of Polymorph Protection
Patent 10,927,129 represents a later-stage patent filing focused on specific, potentially improved, crystalline forms. This strategy aims to create new patent barriers even as earlier patents expire.
- Competitive Advantage: By identifying and patenting Form I and Form II, Novartis sought to secure exclusivity for these particular solid-state forms, potentially offering advantages in terms of stability, manufacturing ease, or pharmacokinetic profiles.
- Generic Challenge: Generic manufacturers aiming to produce imatinib mesylate must carefully analyze the claims of Patent 10,927,129 and other relevant polymorph patents. They need to demonstrate that their generic product does not infringe on these patents, often by developing alternative crystalline forms or processes that avoid the patented subject matter.
Litigation and Patent Expirations
The patent landscape for imatinib mesylate has been a fertile ground for litigation, driven by the high commercial value of the drug.
- Past Litigation: Numerous patent disputes have occurred concerning the validity and infringement of imatinib mesylate polymorph patents. These cases have often focused on the novelty, inventive step, and enablement of the claimed polymorphs, as well as the specificity of their characterization.
- Expiration of Primary Patents: The expiration of Novartis's primary compound and initial polymorph patents has opened the door for generic competition. However, later-stage polymorph patents like 10,927,129 can still influence market entry and exclusivity.
Patent Expiration of 10,927,129
United States Patent 10,927,129 has a statutory expiration date of February 23, 2038, assuming no extensions or challenges that might alter this term. However, the effective market exclusivity can be impacted by factors such as patent challenges, inter partes reviews (IPRs), and the development of non-infringing alternatives by competitors.
Key Takeaways
- Novel Crystalline Forms: Patent 10,927,129 protects two novel crystalline forms of imatinib mesylate, Form I and Form II, defined by specific XRPD and DSC characteristics.
- Enhanced Properties: These forms are claimed to offer improved thermodynamic stability and dissolution profiles compared to existing polymorphs.
- Broad Claim Scope: The patent claims cover the crystalline forms themselves (often via product-by-process), pharmaceutical compositions containing them, and methods of treatment using these forms.
- Competitive Barrier: This patent acts as a significant barrier for generic manufacturers, requiring them to navigate existing polymorph protection to ensure non-infringement.
- Strategic Patenting: The patent exemplifies a strategy of late-stage polymorph patenting to extend market exclusivity for a successful drug.
- Expiration Date: The patent is set to expire in February 2038, but its market impact can be influenced by various legal and commercial factors.
FAQs
-
What is the significance of X-ray powder diffraction (XRPD) data in defining the claimed crystalline forms?
XRPD data is critical because it provides a unique fingerprint for each crystalline form. The specific angles (2-theta values) and intensities of the diffraction peaks reveal the arrangement of molecules within the crystal lattice. For Patent 10,927,129, the XRPD patterns for Form I and Form II are explicitly used in the claims to distinguish them from other known polymorphs, serving as a primary basis for patent protection and infringement analysis.
-
How does Patent 10,927,129 differ from earlier patents covering imatinib mesylate polymorphs like the alpha and beta forms?
Earlier patents focused on different crystalline structures, such as the alpha and beta forms of imatinib mesylate. Patent 10,927,129 claims new, distinct crystalline forms (Form I and Form II) with potentially superior physicochemical properties, such as enhanced thermodynamic stability and dissolution rates. These new forms represent a subsequent layer of patent protection developed after the initial patents expired or were nearing expiration.
-
What challenges do generic manufacturers face in developing imatinib mesylate products in light of Patent 10,927,129?
Generic manufacturers must ensure that their imatinib mesylate product does not infringe on the claims of Patent 10,927,129. This typically involves developing a crystalline form that is not Form I or Form II as defined by the patent's analytical data, or using a manufacturing process that circumvents the patented method. They may need to conduct extensive research to identify alternative, non-infringing polymorphs or amorphous forms and demonstrate their bioequivalence to the innovator product.
-
Can the claims of Patent 10,927,129 be challenged based on prior art related to other imatinib mesylate crystalline forms?
Yes, the validity of any patent, including Patent 10,927,129, can be challenged. Potential challenges could involve demonstrating that Form I or Form II were previously known or obvious in light of existing scientific literature or other patents concerning imatinib mesylate polymorphs. Such challenges might be raised in patent litigation or through post-grant review proceedings like an Inter Partes Review (IPR) at the U.S. Patent and Trademark Office (USPTO).
-
What is the commercial significance of patenting specific crystalline forms of an established drug like imatinib mesylate?
Patenting specific crystalline forms is a crucial strategy for pharmaceutical companies to extend market exclusivity for a successful drug after the primary compound patent expires. These new polymorph forms can offer improved drug properties, such as better stability, solubility, bioavailability, or manufacturing characteristics. By securing patents on these improved forms, the innovator can maintain market control, delay generic competition, and continue to generate revenue from the drug.
Citations
[1] Novartis AG. (2021). Crystalline forms of imatinib mesylate. U.S. Patent 10,927,129. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
